de Vreese K, Kofler-Mongold V, Leutgeb C, Weber V, Vermeire K, Schacht S, Anné J, de Clercq E, Datema R, Werner G
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.
J Virol. 1996 Feb;70(2):689-96. doi: 10.1128/JVI.70.2.689-696.1996.
Bicyclams are a novel class of antiviral compounds which act as potent and selective inhibitors of the replication of human immunodeficiency virus type 1 (HIV-1) and HIV-2. They block an early step in the viral life cycle following adsorption to the CD4 receptor and preceding reverse transcription. To identify the molecular target of these compounds, we genetically analyzed variants of the HIV-1 molecular clone NL4-3, which developed resistance against two structurally related bicyclams, JM2763 and the more potent SID791. The resistant strains were obtained after long-term passaging in MT-4 cells in the presence of progressively increasing compound concentrations. Recombinants between selected genes of the resistant strains and the parental NL4-3 provirus were generated by adapting the marker rescue technique to MT-4 cells. The bicyclam-resistant phenotype was rescued by transferring the envelope gp120 gene of bicyclam-resistant virus into the NL4-3 parental genetic background. In the gp120 genes of the resistant strains, we identified several mutations leading to amino acid substitutions in the V3 loop. Furthermore, two substitutions of highly conserved amino acids in close proximity to the disulfide bridges of the V3 and V4 loops were found in both SID791- and JM2763-resistant strains. Additional mutations in regions encoding V3, C4, V5, and C5 were present in SID791-resistant viruses. Recombination experiments with overlapping parts of the envelope gene indicated that most, if not all, of the mutations were necessary to develop the fully SID791 resistant phenotype. The mutations in the C-terminal part of gp120 downstream of the V3 loop sequence conferred partial resistance to JM2763 but did not significantly decrease susceptibility to SID791. The genetic data and the biological properties of the resistant viruses point to inhibition of entry and fusion as the mode of action of the HIV-inhibitory bicyclams. A possible mechanism of binding of bicyclams to gp120 leading to inhibition of unfolding of gp120 and its shedding from the gp41 fusion domain is discussed.
双环胺是一类新型抗病毒化合物,可作为人类免疫缺陷病毒1型(HIV-1)和HIV-2复制的强效选择性抑制剂。它们在病毒吸附到CD4受体后、逆转录之前阻断病毒生命周期的早期步骤。为了确定这些化合物的分子靶点,我们对HIV-1分子克隆NL4-3的变体进行了基因分析,该变体对两种结构相关的双环胺JM2763和更强效的SID791产生了抗性。抗性菌株是在MT-4细胞中于逐渐增加的化合物浓度存在下长期传代后获得的。通过将标记拯救技术应用于MT-4细胞,产生了抗性菌株的选定基因与亲本NL4-3前病毒之间的重组体。通过将双环胺抗性病毒的包膜gp120基因转移到NL4-3亲本遗传背景中,拯救了双环胺抗性表型。在抗性菌株的gp120基因中,我们鉴定出了几个导致V3环中氨基酸替换的突变。此外,在SID791抗性和JM2763抗性菌株中均发现了V3和V4环二硫键附近高度保守氨基酸的两个替换。SID791抗性病毒中编码V3、C4、V5和C5的区域存在额外突变。包膜基因重叠部分的重组实验表明,大多数(如果不是全部)突变对于产生完全的SID791抗性表型是必需的。V3环序列下游gp120 C末端部分的突变赋予了对JM2763的部分抗性,但并未显著降低对SID791的敏感性。抗性病毒的遗传数据和生物学特性表明,HIV抑制性双环胺的作用方式是抑制病毒进入和融合。讨论了双环胺与gp120结合导致gp120展开抑制及其从gp41融合域脱落的可能机制。